In the newsRegulated drug development

In the news | 10th Aug 2021

Rewriting the BioPharma Rule Book

Danaher Chief Science Officer Jose-Carlos Gutierrez-Ramos explores how the biopharma rule book has been rewritten by the pandemic and what to expect from the future of genomic medicines in this exclusive new article for Pharmaceutical Executive magazine.

Read the article here. 

About IDBSContact us

Innovation and digital transformation will be absolutely vital. We’ve now seen how big data analytics and machine learning/AI can help us understand the spread of disease, map variants, and model enzymes. This technology is being deployed across all parts of the industry, from early drug discovery to large-scale manufacturing. Biopharma cannot transform alone, as we’ve seen in the work of our operating companies with their industry customers. For example, one of Danaher’s operating companies, IDBS, has developed the world’s first biopharma life cycle management system, called IDBS Polar. It’s a new cloud-based data management platform that enables biopharma companies to curate the highly contextualized data needed to support insight, analytics, and machine learning. - Jose-Carlos Gutiérrez-Ramos, PhD

i3 annual event experience IDBS

i3 2023

IDBS is excited to announce that we will be running i3 in person in 2023. It will take place in the US in June. Don’t miss out on more exciting updates, coming soon, by registering your interest below!

Read more